As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
26 Analysts have issued a Cytokinetics, Incorporated forecast:
26 Analysts have issued a Cytokinetics, Incorporated forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 87 87 |
2,608%
2,608%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -563 -563 |
10%
10%
|
|
| EBIT (Operating Income) EBIT | -573 -573 |
9%
9%
|
|
| Net Profit | -752 -752 |
30%
30%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
| Head office | United States |
| CEO | Robert Blum |
| Employees | 498 |
| Founded | 1997 |
| Website | cytokinetics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


